StockpollyBeta
Get App
Popularity #3,164
PRLD · NASDAQ · Biotechnology

Prelude Therapeutics (PRLD)

Develops small-molecule oncology programs centered on JAK2V617F inhibition and KAT6A degradation.

$4.30
vs last close−0.55 (−11.32%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000034007656
Cost of revenue000000000000
Gross profit000034007646
333734373738353227231821
Research & development263027302932292622181416
777886665555
Selling & marketing000000000000
General & administrative707886665555
Other expenses000000000000
Operating income−33−37−34−37−34−34−35−32−20−17−14−15
343225311142
Other non-operating income0−4−3−2−2−5−3−1−1−1−4−2
Income before tax−31−33−31−35−32−29−32−31−20−16−10−14
Net income from continuing operations−31−33−31−35−32−29−32−31−20−16−10−14
Net income−31−33−31−35−32−29−32−31−20−16−10−14
EPS, basic−$0.45−$0.48−$0.42−$0.46−$0.43−$0.38−$0.42−$0.41−$0.26−$0.26−$0.13−$0.14
EPS, diluted−$0.45−$0.48−$0.42−$0.46−$0.43−$0.38−$0.42−$0.41−$0.26−$0.26−$0.13−$0.14
Weighted average shares, basic687076767676767676638398
Weighted average shares, diluted687076767676767676638398
EBITDA−33−33−31−34−32−28−32−31−19−16−10−14
Depreciation & amortization000000000000
EBIT−33−33−31−35−32−29−32−31−20−16−10−14